South African and Swiss teams claim new agents for malaria

4 Sep 2013 - 19:00

Two scientists at the University of Cape Town, Kelly Chibale and Yassir Younis, together with scientists from Medicines for Malaria Venture (MMV) in Geneva, have jointly created novel aminopyrazine derivatives that are back-up compounds to the clinical candidate MMV390048 for use for the treatment of malaria, reports Thomson Reuters Drug News on Sep 03, 2013. The compound was shown to inhibit the proliferation of Plasmodium falciparum in infected human red blood cells, as well as inhibiting parasite levels in the blood of mice infected by Plasmodium berghei.

UCT and MMV co-applied for patent protection for this compound in 2012 and the patent application has now been published as WO2013121387.